More relevantly, Furlan et al. reported that EP300/CREBBP inhibitors mediate the MYC/ribosomal protein axis in enzalutamide-resistant cells and might have promising therapeutic implications in prostate cancer [34]. The gene discussed is EP300; the disease is prostate cancer.